FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

The Food and Drug Administration granted accelerated approval to Etcamah, known scientifically as camizestrant, for use alongside any of three widely used CDK4/6 inhibitors in adult patients whose tumors carry a particular genetic change called an ESR1 mutation.

Why This Approval Matters

Breast cancer remains the most frequently diagnosed malignancy among women in the United States, with more than 300,000 new cases identified each year and over 42,000 deaths. The majority of these cancers are driven by estrogen, meaning they grow in response to the hormone and can be slowed or controlled by therapies that block estrogen's effects.

For decades, the standard first-line treatment for this hormone receptor-positive, HER2-negative form of metastatic disease has been an aromatase inhibitor paired with a CDK4/6 inhibitor, a combination that has extended survival for many patients.

But not all tumors respond the same way, and resistance often develops. One of the most important drivers of that resistance is a change in a gene called ESR1, which encodes the estrogen receptor itself. When this gene mutates during treatment, the receptor can stay active even when estrogen levels are low, allowing the cancer to keep growing despite therapy. These mutations tend to emerge over time as the disease evolves, and they are linked to worse outcomes.

Roughly 30 percent of patients whose cancer initially responds to endocrine therapy will develop an ESR1 mutation before their disease progresses, and once that happens, options become limited and survival rates drop sharply, with just over a third of patients expected to live beyond five years after diagnosis.

How the New Approach Works

Etcamah belongs to a newer class of drugs called selective estrogen receptor degraders, or SERDs. Unlike older endocrine therapies that simply block estrogen from binding to its receptor, SERDs go a step further by forcing the receptor to be destroyed inside the cell.

Camizestrant is a next generation oral SERD taken once daily at a dose of 75 milligrams. When combined with a CDK4/6 inhibitor, the goal is to hit the cancer from two angles at once, shutting down estrogen signaling while also blocking a key pathway that drives cell division.

What the SERENA-6 Trial Found

The approval is based on a large, randomized, double blind, placebo controlled Phase 3 study called SERENA-6, which enrolled patients with estrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer who were already receiving an aromatase inhibitor plus a CDK4/6 inhibitor. Those found to have an emerging ESR1 mutation in their blood were then randomized to either switch to camizestrant plus their existing CDK4/6 inhibitor or to continue their current regimen unchanged.

Patients who moved to the camizestrant combination faced a 56 percent lower risk of their cancer progressing or of dying during the study period compared with those who stayed on standard therapy, a difference reflected in a hazard ratio of 0.44.

In practical terms, that translated into a median progression-free survival of 16.0 months for patients on the camizestrant arm versus 9.2 months for those who continued their original treatment.

The benefit held up consistently no matter which CDK4/6 inhibitor the patient was taking, and it was seen across subgroups defined by age, race, geographic region, when the mutation was detected, and what type of ESR1 mutation was present.

Longer Term Outcomes Still Maturing

While the primary endpoint focused on how long patients lived without their disease worsening, the trial also tracked what happens after the first progression, known as time to second progression or PFS2, as well as overall survival. At the time of the initial analysis, those data were not yet mature enough to draw firm conclusions.

However, a later pre-planned look showed that patients who started on camizestrant went on to live a median of 25.7 months before experiencing a second progression, compared with 19.1 months for those on standard care.

Overall survival data continue to accumulate and currently favor the camizestrant combination, with a hazard ratio of 0.87 and a confidence interval that has not yet crossed the threshold for statistical significance. The study will keep following patients to see whether that early signal strengthens into a clear survival advantage.

A Companion Test to Guide Treatment

Alongside approving the drug, the FDA also cleared a companion diagnostic assay called Guardant360 CDx, which can detect emerging ESR1 resistance mutations in circulating tumor DNA from patients with hormone receptor positive, HER2 negative advanced or metastatic breast cancer. The test is intended to be used during first-line therapy to identify patients who would benefit from switching to Etcamah before their cancer shows signs of progression on imaging or clinical exam.

Where Else Etcamah Is Approved

Etcamah in combination with a CDK4/6 inhibitor is already approved in the European Union, Japan, and several other countries for a similar indication, covering adult patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer upon detection or emergence of an ESR1 mutation without disease progression during first-line endocrine therapy. The US approval aligns with those earlier decisions and adds the world's largest oncology market to the list of places where this approach is available.